Shanghai Shucan Industrial Co.,Ltd
|Place of Origin:||China|
|Minimum Order Quantity:||10gram|
|Packaging Details:||discreet and safe foil bag or tin (as your requirment )|
|Delivery Time:||Within 12hours after payment|
|Payment Terms:||T/T, , MoneyGram and bank transfer|
|Supply Ability:||5000kilogram per month|
|Molecular Formula:||C28H27NO4S||Molecular Weight:||C28H27NO4S|
|Appearance:||Light Yellow Crystalline Powder||Standard:||Enterprise Standard|
|Packing:||As Per Your Requirements||Application:||Pharmaceutical Intermediate|
|Packaging Details:||Very Discreet. As Required.||Payment Terms:||T/T, , MoneyGram, Bitcoin|
anti estrogen steroid,
breast cancer steroids
Amino Acid Nutrient Raloxifene Pharm Intermiediate
Product name: Raloxifene
CAS No.: 84449-90-1
Appearance: light yellow crystalline powder
USES: Raloxifene will be like tamoxifen as effective, and less adverse effects.
Raloxifene is contraindicated in lactating women or women who are or may become pregnant, in women with active or past history of venous thromboembolic events, including deep vein thrombosis,pulmonary embolism, and retinal vein thrombosis and in women known to be hypersensitive to raloxifene.
For the prevention and treatment of osteoporosis in postmenopausal women; reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis; reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.
May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e. G., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.
Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.
Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes. Raloxifene is a teratogenic drug, i. e., can cause developmental abnormalities such as birth defects.
|Exemestane Acatate||CAS: 107868-30-4|
|Nandrolone phenypropionate /Durabolin|
Boldenone undecylenate (Equipoise)
|Trenbolone Hexahydrobenzyl Carbonate||CAS: 23454-33-3|
Methenolone Enanthate (Primobolan)
|Tamoxifen Citrate /Nolvadex||CAS: 54965-24-1|
|Shanghai Shucan Industrial Co.,LTD.|
|lareina (Sales Manger)|
|No.19 Building,28 Lane Beiyu Road,Changning District,Shanghai, China|
Transportation you may like: